Discovering New Therapeutic Uses for Existing Molecules
Discovering New Therapeutic Uses for Existing Molecules (Therapeutics Discovery) is a collaborative pilot program designed to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutics development. This innovative program matches researchers with a selection of molecular compounds from industry to test ideas for new therapeutic uses, with the ultimate goal of identifying promising new treatments for patients.
NCATS has collaborated with eight companies, including AbbVie (formerly Abbott), AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, L.L.C., Pfizer, and Sanofi. Collectively, these companies have agreed to make 58 of these compounds available for the pilot program. The compounds have undergone significant research and development by industry, including safety testing in humans, providing a strong starting point for scientists and permitting the process to move more rapidly.
Through the Therapeutics Discovery program, NCATS is re-engineering the way the various sectors collaborate. Not only does the program seek to match novel scientific ideas to existing compounds, but it also provides template agreements, reducing the negotiation time that could otherwise delay the research.
In Fiscal Year 2013, for the initial pilot phase, NCATS will provide up to $20 million to fund two- to three-year staged, cooperative agreement research grants. Learn more about Therapeutics Discovery funding information. There are no active funding announcements at this time. Below are archived opportunities that have expired:
NOT-TR-12-010: Technical Assistance Webinar for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules Limited Competition RFA-TR-12-004 (UH2/UH3) and RFA-TR-12-005 (UH3)
Library of Agents
The Therapeutics Discovery library of industry-provided agents features compounds and biologics that have undergone significant pre-clinical and
Phase I testing and are ready for additional testing in humans.
To facilitate and speed collaboration, NIH has developed template agreements designed to streamline the legal and administrative process for participation by multiple organizations.
For More Information
Frequently Asked Questions
- About Therapeutics Discovery
- About the UH2/UH3 and UH3 Limited Competition Application (Expired December 18, 2012)
- About the X02 Pre-Application PAR-12-203 (Expired August 15, 2012)
Technical Assistance Webinar
NCATS held a Therapeutics Discovery technical assistance webinar on Monday, June 25, 2012. Download the slides from this event.
Join the NCATS Listserv
Stay informed and keep updated about the latest news, funding announcements, and collaboration opportunities by signing up for one of NCATS' list servs. Join the NCATS announcement listserv for funding related news and subscribe to the e-newsletter listserv for the Center's latest news and announcements.